Drug Profile
Research programme: integrin inhibitors - Allocyte Pharmaceuticals
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator Allocyte Pharmaceuticals
- Developer AlloCyte Pharmaceuticals
- Class Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 11 Sep 2023 Preclinical development is ongoing in Switzerland (PO) (Allocyte Pharmaceuticals pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Immunological-disorders in Switzerland (PO)
- 21 Jul 2016 Preclinical trials in Immunological disorders in Switzerland (PO) before July 2016